Search

Objectives: To clarify the impact of histological grades in follicular lymphoma. Methods: We retrospectively analysed 250 patients diagnosed with FL treated with chemoimmunotherapy: 188 patients were grades 1‐2 and 62 grade 3A. Results: In our series, grade 3A FL patients were older, higher proportion of localised disease and lower bone marrow infiltration at diagnosis comparing grades 1‐2 FL patients. Estimated six‐year progression‐free survival and time to progression showed no differences between both groups [grade 3A: 56% (95%CI: 39%‐73%) and 51% (95%CI: 41%‐61%) vs grades 1‐2:55% (95%CI: 46%‐63%) and 57% (95%CI: 49%‐65%), P =.782 and P =.521, respectively]. Estimated six‐year overall survival was lower, 76% (95%CI: 64%‐88%) for the grade 3A group than grades 1‐2 83% (95%CI: 77%‐89%); P =.044. In addition to that, cumulative incidence curves of death not related to lymphoma at 10 years between groups were as follows: [0.26 (95%CI: 0.25‐0.27) and 0.05 (95%CI: 0.04‐0.06) for G3AFL and G1‐2FL, respectively], P =.010. Grade 3A FL showed in PFS curve no relapses after 6 years. These results were absolutely reproduced in 199 patients receiving R‐CHOP regimen as induction. Conclusions: Our results indicate similar long‐term outcomes in terms of progression‐free survival and time to progression in grades 1‐2 and 3A. No relapses were observed in G3AFL group after 6 years. [ABSTRACT FROM AUTHOR]

Introduction: Inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) is a rare poor prognosis cytogenetic abnormality present in acute myeloid leukemia (AML) and other myeloid neoplasms., Objective: The aim of this study was to evaluate the outcome of a cohort of 61 patients with newly diagnosed AML with inv(3)/t(3;3) treated with homogeneous intensive chemotherapy protocols conducted by the Spanish PETHEMA and CETLAM cooperative groups between 1999 and 2017., Methods: In this retrospective study the main clinical and biologic parameters were collected. The complete response (CR) rate, the cumulative incidence of relapse (CIR) and the overall survival (OS) were calculated. An analysis of prognostic factors for survival was performed., Results: Sixty-one patients received induction and only 18 (29%) achieved CR (median age, 46 years). Allogeneic hematopoietic stem cell transplantation (alloHSCT) was performed in 36 patients (59%), 15 with active disease. One- and 4-year CIR were 52% and 56%. One- and 4-year OS probabilities were 41% and 13%. By multivariate analysis monosomal karyotype (MK) was associated with poorer OS (HR 2.0, P = .017)., Conclusion: Inv(3)/t(3;3) AML is a poor prognosis entity with low response to standard chemotherapy and to alloHSCT because of frequent and early relapse. MK was associated with a poorer prognosis. Improved therapeutic strategies are clearly needed., (© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)